Osteoarthritis and Cartilage
Volume 18, Issue 3 , Pages 289-296 , March 2010

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials

  • E.M. Bartels

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • Copenhagen University Library, Denmark
    • Corresponding Author InformationAddress correspondence and reprint requests to: Else Marie Bartels, The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, DK-2000 F, Denmark. Tel: 45-38164198; Fax: 45-38164159.
    • ,
  • H. Bliddal

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • Center for Sensory-Motor Interaction, Aalborg University, Denmark
    • ,
  • P.K. Schøndorff

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • ,
  • R.D. Altman

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    • ,
  • W. Zhang

      Affiliations

    • Academic Rheumatology, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham, UK
    • ,
  • R. Christensen

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Denmark

Received 3 June 2009 ,Accepted 9 October 2009.

References 

  1. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005;365(9463):965–973
  2. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991;27:10–12
  3. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15(9):981–1000
  4. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162
  5. Blandizzi C, Tuccori M, Colucci R, Fornai M, Antonioli L, Ghisu N, et al. Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacol Res. 2009;59(2):90–100
  6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959
  7. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997;24(4):799–802
  8. Hunter DJ, Hellio Le Graverand-Gastineau MP. How close are we to having structure-modifying drugs available?. Med Clin North Am. 2009;93(1):223–234
  9. Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med. 1995;40:365–394
  10. Krane SM. Clinical importance of metalloproteinases and their inhibitors. Ann N Y Acad Sci. 1994;732:1–10
  11. Lotz M, Blanco FJ, von Kempis J, Dudler J, Maier R, Villiger PM, et al. Cytokine regulation of chondrocyte functions. J Rheumatol Suppl. 1995;43:104–108
  12. Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum. 1997;40(11):2065–2074
  13. Kronheim SR, Mumma A, Greenstreet T, Glackin PJ, Vanness K, March CJ, et al. Purification of interleukin-1-beta converting enzyme, the protease that cleaves the interleukin-1-beta precursor. Archiv Biochem Biophys. 1992;296(2):698–703
  14. Curtis CL, Rees SG, Little CB, Flannery CR, Hughes CE, Wilson C, et al. Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n − 3 fatty acids. Arthritis Rheum. 2002;46(6):1544–1553
  15. Martel-Pelletier J, McCollum R, Dibattista J, Faure MP, Chin JA, Fournier S, et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum. 1992;35(5):530–540
  16. Boittin M, Redini F, Loyau G, Pujol JP. Effect of diacerhein (ART 50) on the matrix synthesis and collagenase secretion by cultured joint chondrocytes in rabbits. Rev Rhum Ed Fr. 1993;60(6 Pt 2):68S–76S
  17. Charbit S, Schutze F, Taccoen A, Pelletier J, Provvedini D. Preventing and/or limiting joint cartilage degradation, useful in the treatment of osteoarthritis, using rhein or its derivative as interleukin-1 inhibitor. NEGMA, L.E.R.A. and LAB, N.E.G.M. [WO200222119-A; EP1317263-A; WO200222119-A1; AU200190033-A; EP1317263-A1; US6610750-B1; MX2003002242-A1].
  18. Pujol JP, Chadjichristos C, Legendre F, Bauge C, Beauchef G, Andriamanalijaona R, et al. Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res. 2008;49(3):293–297
  19. Franchi-Micheli S, Lavacchi L, Friedmann CA, Zilletti L. The influence of rhein on the biosynthesis of prostaglandin-like substances in-vitro. J Pharm Pharmacol. 1983;35(4):262–264
  20. Petrillo M, Montrone F, Ardizzone S, Caruso I, Porro GB. Endoscopic Evaluation of diacetylrhein-induced gastric-mucosal lesions. Curr Ther Res Clin Exp. 1991;49(1):10–15
  21. Pavelka K, Trc T, Karpas K, Vitek P, Sedlackova M, Vlasakova V, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007;56(12):4055–4064
  22. Fidelix TSA, Soares BGDO, Trevisani VFM. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006;1:
  23. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Archiv Intern Med. 2006;166(17):1899–1906
  24. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–605
  25. Jüni P, Altman DG, Egger M. Systematic reviews in health care – assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42–46
  26. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 15-2-1999;18(3):321–359
  27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. second edn.. Philadelphia,: Lawrence Earlbaum Associates; 1988;
  28. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Stat Med. 15-8-2002;21(15):2131–2144
  29. Hedges LV. Distribution theory for glass's estimator of effect size and related estimators. J Educ Stat. 1981;6(2):107–128
  30. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21(11):1575–1600
  31. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–129
  32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188
  33. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558
  34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560
  35. Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399–408
  36. Wang MC, Bushman BJ. Integrating Results through Meta-Analytic Review Using SAS Software. first edn.. Cary, NC: SAS Institute Inc; 1999;
  37. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS for Mixed Models. second edn.. Cary, NC: SAS Institute Inc; 2006;
  38. Functional manifestations of osteoarthritis . key points to the clinical efficacy of diacerhein. Presse Med. 1998;27(25):1302–1304
  39. Brun PH. Effect of diacetylrhein on the development of experimental osteoarthritis. A biochemical investigation. Osteoarthritis Cartilage. 1997;5(4):289–291
  40. Lequesne M, Taccoen A. Clinical and radiographic status of patients in the ECHODIAH study who underwent THA Pertinence of the pain-function index for operative decision making. Presse Med. 2002;31(39 Pt 2):S18–S19
  41. Mazieres B, Garnero P, Gueguen A, Abbal M, Berdah L, Lequesne M, et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis. 2006;65(3):354–359
  42. Provvedini D, Cohen P. Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis. Presse Med. 2002;31(39 Pt 2):S13–S15
  43. Solignac M. Mechanisms of action of diacerein, the first inhibitor of interleukin-1 in osteoarthritis. Presse Med. 2004;33(9 Pt 2):S10–S12
  44. Van den Berg WB. Mechanisms of action of diacerein, the first inhibitor of interleukin-1 in osteoarthritis. Presse Med. 2004;33(9):S10–S12
  45. Vignon E. Results of ECHODIAH study in hip osteoarthritis. Presse Med. 2002;31(1):7–9
  46. Villani P, Bouvenot G. Assessment of the placebo effect of symptomatic slow-acting anti-arthritics. Presse Med. 1998;27(5):211–214
  47. Kay AG, Griffiths LG, Volans GN, Grahame R. Preliminary experience with diacetylrhein in the treatment of osteoarthritis. Curr Med Res Opin. 1980;6(8):548–551
  48. Leblan D, Chantre P, Fournie B. Harpagophytum procumbens in the treatment of knee and hip osteoarthritis. Four-month results of a prospective, multicenter, double-blind trial versus diacerhein. Joint Bone Spine. 2000;67(5):462–467
  49. Lingetti M, Dambrosio PL, Digrezia F, Sorrentino P, Lingetti E. A controlled-study in the treatment of osteoarthritis with diacetylrhein (artrodar). Curr Ther Res Clin Exp. 1982;31(3):408–412
  50. Mazzaro C, Bocchieri E, Tesolin GF, Ventre L, Romagnoli A. Clinical evaluation of diacerein in the treatment of osteoarthrosis. Minerva Med. 1989;80(9):1025–1027
  51. Paresce E, Angelini M, Carabba M. Evaluation of clinical effectiveness and tolerability of diacerhein retard in knee arthrosis. G Ital Ric Clin Terapeut. 1992;13(6):151–156
  52. Pelletier JP, Yaron M, Cohen P. Treatment of osteoarthritis of the knee diacerein: a double-blind, placebo controlled trial. Arthritis Rheum. 1999;42(9):S295
  53. Tang FL, Wu DH, Lu ZG, Huang F, Zhou YX. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee. Poster presented at the 11th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, ICC, Jeju, Korea, 11–15th September 2004.
  54. Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006;21(2):75–80
  55. Agrati AM, Palmieri G, Vargiu A. Clinical evaluation of galactosamine-glucoronoglycan sulphate in osteoarthritis. A controlled study vs diacerein. Gazz Med Ital Arch Sci Med. 1995;154(5–6):209–212
  56. Cao X. Clinical observation of Diacerein and sodium hyaluronate via interarticular injection on knee osteoarthritis. Xiandai Zhongxiyi Jiehe Zazhi. 2007;16:5399–5401
  57. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000;7(3):177–183
  58. Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007;15(6):605–614
  59. Marcolongo R, Fioravanti A, Adami S, Tozzi E, Mian M, Zampieri A. Efficacy and tolerability of diacerhein in the treatment of osteoarthrosis. Curr Ther Res Clin Exp. 1988;43(5):878–887
  60. Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004;63(12):1611–1617
  61. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339–2348
  62. Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994;37(4):529–536
  63. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis – ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44(11):2539–2547
  64. Lequesne M, Berdah L, Gerentes I. Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis. Rev Prat. 1998;48(17):S31–S35
  65. Schulitz KP. Clinical investigation of the efficacy and tolerance of diacetylrhein (DAR) in the treatment of osteoarthritis of the knee. Unpublished final clinical study report, October 27 ed., Madaus AG, Köln, Germany, 1994.
  66. Ascherl R. Double-blind, placebo-controlled multicentre, phase iii study of the efficacy and tolerability of diacerein (DA39) in patients with osteoarthritis of the knee. Unpublished clinical study report., October 10 ed. Madaus AG, Köln, Germany, 1994.
  67. Kruse R, Essen-Gustavsson B, Fossum C, Jensen-Waern M. Blood concentrations of the cytokines IL-1beta, IL-6, IL-10, TNF-alpha and IFN-gamma during experimentally induced swine dysentery. Acta Vet Scand. 2008;50:32
  68. Cutler SA, Lonergan SM, Cornick N, Johnson AK, Stahl CH. Dietary inclusion of colicin E1 is effective in preventing postweaning diarrhoea caused by F18-positive Escherichia coli in pigs. Antimicr Agents Chemother. 2007;51(11):3830–3835
  69. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52(4):523–526
  70. Woolf AD. Healthcare services for those with musculoskeletal conditions: a rheumatology service. Recommendations of the European Union of Medical Specialists Section of Rheumatology/European Board of Rheumatology 2006. Ann Rheum Dis. 2007;66(3):293–301
  71. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–656
  72. Lin FY, Zhang WY, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329(7461):324–326
  73. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51(5):746–754
  74. Herndon CM, Hutchison RW, Berdine HJ, Stacy ZA, Chen JT, Farnsworth DD, et al. Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2008;28(6):788–805

PII: S1063-4584(09)00278-7

doi: 10.1016/j.joca.2009.10.006

Osteoarthritis and Cartilage
Volume 18, Issue 3 , Pages 289-296 , March 2010

Article Tools

* Image Usage & Resolution